MTEM vs. FBIO, TNXP, HEPA, TRVN, CVKD, SEEL, AEZS, ABVC, CMMB, and BNOX
Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Fortress Biotech (FBIO), Tonix Pharmaceuticals (TNXP), Hepion Pharmaceuticals (HEPA), Trevena (TRVN), Cadrenal Therapeutics (CVKD), Seelos Therapeutics (SEEL), Aeterna Zentaris (AEZS), ABVC BioPharma (ABVC), Chemomab Therapeutics (CMMB), and Bionomics (BNOX). These companies are all part of the "pharmaceutical preparations" industry.
Fortress Biotech (NASDAQ:FBIO) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.
Molecular Templates has a net margin of -49.57% compared to Molecular Templates' net margin of -96.71%. Fortress Biotech's return on equity of 0.00% beat Molecular Templates' return on equity.
Fortress Biotech currently has a consensus price target of $41.25, indicating a potential upside of 1,927.03%. Given Molecular Templates' higher probable upside, equities analysts clearly believe Fortress Biotech is more favorable than Molecular Templates.
Fortress Biotech has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Molecular Templates received 19 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 65.12% of users gave Fortress Biotech an outperform vote.
96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 26.9% of Fortress Biotech shares are held by company insiders. Comparatively, 18.7% of Molecular Templates shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Fortress Biotech has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
In the previous week, Fortress Biotech had 6 more articles in the media than Molecular Templates. MarketBeat recorded 9 mentions for Fortress Biotech and 3 mentions for Molecular Templates. Fortress Biotech's average media sentiment score of 1.43 beat Molecular Templates' score of 0.19 indicating that Molecular Templates is being referred to more favorably in the news media.
Summary
Fortress Biotech beats Molecular Templates on 10 of the 17 factors compared between the two stocks.
Get Molecular Templates News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Molecular Templates Competitors List
Related Companies and Tools